Overview

Improving Diagnosis and Management of Chronic Idiopathic Constipation Across Diverse Patient Populations

Click the"View Activity" button to view this activity.

View Activity

Activity already occured. CME/CE is no longer available for this activity

Format

Interactive Practice Guide

Time to Complete

2.50 hr(s).

Release Date

December 19, 2023

Expires On

December 19, 2024

Can you differentiate between chronic idiopathic constipation (CIC) and other conditions characterized by constipation to ensure your patients receive timely and appropriate interventions? Access these educational resources and tools to help you enhance diagnostic processes, management strategies, and multidisciplinary care. Then share this invaluable educational content with your team by using the downloadable discussion guides and slide decks to initiate meaningful conversations. Do you have questions about optimizing your EMR workflow? We’ll provide you with practical guidance for integrating clinical tools, algorithms, and alerts within your system. Are your patients frustrated and looking for answers? Empower your patients to make informed decisions about various treatment options by sharing the essential resources provided.

Claim credit ranging from 0.25 to a maximum of 2.50 for your participation in this activity!

This activity is intended for HCPs who treat CIC including gastroenterologists, PCPs, and the multidisciplinary team.

Chronic idiopathic constipation (CIC) is a functional gastrointestinal disorder characterized by lack of periodicity in defecating as well as pain or difficulty in defecating that cannot be attributed to a physiologic, anatomic, radiologic, or histologic etiology. This disorder affects 14% of persons worldwide and 9% to 20% of adults in the US. In addition, diagnosis of CIC can be complex, requiring the exclusion of a wide variety of underlying conditions. To ensure that patients with CIC receive timely interventions and the best possible care, clinicians (including gastroenterologists, primary care physicians, and advanced practice providers) need to better distinguish CIC from similar conditions. Clinicians need to understand recently updated CIC guidelines and select appropriate therapies according to mechanisms of action, safety profiles, clinical trial efficacy, and real-world data. Finally, through education on the application of shared decision-making approaches in CIC, patients and clinicians can work together to avoid delays in appropriate treatment and achieve treatment goals.

Upon completion of this activity, learners will be able to:
• Differentiate CIC from other disorders with overlapping symptoms
• Identify the mechanisms of action as well as clinical and real-world evidence with the available CIC agents
• Formulate individualized treatment regimens for patients with CIC
• Incorporate meaningful communication and SDM into the management of CIC

Provided by The University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL).

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Brooks Cash, MD, AGAF, FACG, FACP, FASGE
Professor of Medicine
University of Texas McGovern Medical School
Chief, Division of Gastroenterology, Hepatology, and Nutrition
University of Texas Health Science Center at Houston
Houston, TX

Lucinda Harris, MS, MD

Professor of Medicine

Division of Gastroenterology and Hepatology

Mayo Clinic Alix School of Medicine

Scottsdale, AZ

The University of Chicago Pritzker School of Medicine requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

The following financial relationships have been provided:

Brooks Cash, MD, (Chair)

Consultant: Abbvie, Ardelyx, Salix, Vibrant

Speakers' Bureau: Abbvie, Ardelyx, QOL Medical, Salix

Lucinda Harris, MS, MD, (Faculty)

Advisory Board: Ardelyx, Salix

Advisor: QOL Medical

Consultant: Gemelli

Research- Celiac Study: Takeda

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Tenapanor is not approved for the treatment of CIC.

University of Chicago Pritzker School of Medicine staff members, ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Completion of all video modules are expected to take up to 2.5 hours to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

For questions, contact Michelle Forcier at mforcier@achlcme.org.

The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Healthcare Professional Credit
Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.

Michelle Forcier
mforcier@achlcme.org

Overview

Improving Diagnosis and Management of Chronic Idiopathic Constipation Across Diverse Patient Populations

Program Description

Intended Audience

Activity Purpose

Learning Objectives

Provider Information

Supporter Information

Faculty

Faculty Disclosure

Staff Disclosure

Disclaimer

Method of Participation

Accreditation and Credit Designation

Program Manager

Related Activities